Pulmonary vasodilator therapy in COPD-associated pulmonary hypertension: A real-world case series of 14 patients confirmed by right heart catheterization Authors: Michael Vera Ricaurte, Esteban Kosak Lopez, Andrew Geller, Raul Leguizamon, Justin Lam, Thitiphan Srikulmontri, Maria Helena Siqueira Tavares de Melo, Thomas Stavola, John Malin, Jose M. Martinez-Manzano, Enrique Pacheco Published: 2026 ABSTRACT RationalePulmonary vasodilator therapy in chronic obstructive pulmonary disease-associated pulmonary hypertension (COPD-PH) remains controversial, and real-world data describing which patients are selected for treatment after invasive hemodynamic confirmation are limited. We present a single-center case series of patients with RHC-confirmed COPD-PH treated with pulmonary vasodilators, focusing on clinical phenotype, hemodynamic profile, treatment patterns, and short-term outcomes.MethodsWe conducted a retrospective case series of adults with COPD-associated PH identified by right heart catheterization (RHC) between 2018 and 2023. Patients with isolated precapillary PH or combined pre- and postcapillary PH treated with pulmonary vasodilators within 1 month of RHC were included. Outcomes included major adverse cardiovascular events (MACE), all-cause mortality, and pulmonary complications.ResultsAmong 200 patients with COPD-PH and a precapillary component, 14 patients (7%) received pulmonary vasodilator therapy after RHC and comprised the case series. Most had isolated precapillary PH (71%), severe PH by prior criteria (71%), and frequent cardiopulmonary comorbidities. Sildenafil monotherapy was used in 13/14 patients, while one received sildenafil plus macitentan. At 1-year follow-up, 5/13 patients with available data developed MACE, including 3 heart failure hospitalizations and 2 cardiovascular deaths. Among 4 patients with repeat RHC, 3 had higher PVR on follow-up evaluation.ConclusionPulmonary vasodilator therapy was used in a small, highly selected subset of patients with RHC-confirmed COPD-PH. Treated patients had heterogeneous hemodynamic profiles and frequent cardiovascular events during follow-up, supporting the need for careful phenotyping and prospective studies. Introduction Pulmonary hypertension (PH) is a prevalent complication in patients with chronic obstructive pulmonary disease (COPD) associated with worse functional status and increased mortality [1]. Most patients with COPD-associated PH (COPD-PH) only develop relatively mild elevations in their pulmonary vascular resistance (PVR) and pulmonary artery (PA) pressure as a result of airway or parenchymal disease severity, leading to alveolar hypoxia and hypoxic pulmonary vasoconstriction.Additionally, COPD frequently coexists with several cardiovascular comorbidities, leading to left ventricular (LV) dysfunction and elevated left-sided filling pressures, further contributing to the development of PH [2]. However, a subgroup of patients with COPD, estimated to be less than 5%, develop pulmonary vasculopathy that is disproportionate to their underlying lung disease severity and unrelated to left heart disease [2]. Patients within this group, known as the “vascular phenotype,” often suffer marked hemodynamic impairment and are at risk of developing right ventricular (RV) failure and death [3]. This group has been the focus of studies evaluating the efficacy and safety of pulmonary vasodilators. The “PERFECT” trial, a recent randomized controlled trial of inhaled treprostinil in COPD-associated PH, was stopped early due to futility and potential harm [4]. Conversely, another recent large observational study suggested a possible survival benefit among patients with COPD-associated PH who received phosphodiesterase-5 inhibitor (PDE5i) therapy [5]. In real-world settings, the use of pulmonary vasodilators in patients with COPD-associated PH remains controversial given their inconsistent clinical benefits, concerns regarding worsening hypoxemia from ventilation-perfusion mismatch, and the risk of precipitating left heart disease decompensation owing to the high prevalence of cardiovascular comorbidities in this population [[6], [7], [8]]. Despite these concerns, features of PH severity, including hemodynamic data (such as mPAP and PVR) and imaging findings (such as PA diameter and RV size), are associated with adverse outcomes in patients with COPD [3]. Although randomized trials and registry studies have evaluated pulmonary vasodilators in COPD-PH, less is known about how these therapies are used in routine practice, particularly in patients with invasive hemodynamic confirmation, mixed cardiopulmonary comorbidities, and care outside specialized PH trial settings. This gap is clinically relevant because treatment decisions in COPD-PH often occur in heterogeneous patients who may not resemble trial populations. Therefore, we present a single-center case series of 14 patients with RHC-confirmed COPD-PH treated with pulmonary vasodilators, emphasizing patient-level clinical phenotype, hemodynamic profile, treatment selection, and 1-year outcomes. Methods We conducted a retrospective single-center case series at Jefferson Einstein Philadelphia Hospital of adult patients with chronic obstructive pulmonary disease-associated pulmonary hypertension confirmed by right heart catheterization between January 2018 and December 2023 who were treated with pulmonary vasodilator therapy after RHC. Patients undergoing RHC were initially identified using Current Procedural Terminology (CPT) codes and screened for COPD based on International Classification of Diseases (ICD-10) codes. Subsequently, through chart review, we included only patients with a confirmed COPD diagnosis, based on a history of smoking (current or former), together with either spirometric evidence of airflow obstruction (FEV1/FVC <0.70) or radiographic evidence of emphysema on chest CT. Isolated precapillary PH was defined as a mean pulmonary artery pressure (mPAP) of >20 mmHg, pulmonary vascular resistance (PVR) of >2 Wood units (WU), and pulmonary arterial wedge pressure (PAWP) of ≤15 mmHg, whereas combined pre- and post-capillary PH was defined as a mPAP of >20 mmHg, PVR >2 WU, and PAWP >15 mmHg. Severe PH was defined as PVR ≥5 Wood units, consistent with prior studies describing the severe pulmonary vascular phenotype in PH associated with lung disease [5]. In patients with multiple RHC during the study period, the earliest catheterization data were considered as baseline, and subsequent RHC were used as follow-up data. Baseline demographics, smoking history, and cardiopulmonary comorbidities were obtained from the electronic health record at the time of the index RHC through chart review. Heart failure with reduced and preserved ejection fraction were defined as a left ventricular ejection fraction of less than 40% and greater than 50%, respectively. Pulmonary function test (PFT) data closest to the RHC, including spirometry, lung volumes, and diffusion capacity of carbon monoxide (DLCO), were obtained when available. Transthoracic echocardiography (TTE) data were obtained from routine clinical care. The estimated pulmonary artery systolic pressure (PASP) was calculated using the modified Bernoulli equation (PASP = 4∗[TRV]2+RAP). RV dilation was defined as a right ventricle (RV) to left ventricle (LV) ratio of >1:1. RV strain was most commonly defined qualitatively based on visual inspection of the RV. Initiation of pulmonary vasodilator therapy was recorded from discharge documentation or outpatient follow-up within 1 month of the index RHC. We gathered information regarding dosing, frequency, and route of administration. Clinical outcomes at 1-year follow-up were obtained through chart review from the institutional electronic medical records and included all-cause mortality, major adverse cardiovascular events (MACE), and pulmonary complications. MACE was defined as a composite of myocardial infarction, heart failure exacerbation requiring hospitalization, stroke, and cardiovascular death. Pulmonary outcomes included COPD exacerbations and episodes of hypoxic or hypercapnic respiratory failure, with or without the need for invasive mechanical ventilation/ICU admission, and not related to cardiovascular outcomes. Because of the case-series design and small sample size, no comparative or inferential analyses were performed. Data were presented using descriptive statistics; continuous variables were reported as median (range), and categorical variables as frequencies and percentages. The study was approved by the Jefferson Institutional Review Board (iRISID-2024-1574). Results Of 355 patients with COPD who underwent RHC, 200 had a precapillary PH component (98 with isolated precapillary PH and 102 with combined pre- and postcapillary PH). Only 14 (7%) received pulmonary vasodilator therapy and comprised the final study cohort. This low treatment frequency illustrates the selective use of pulmonary vasodilators in routine practice among patients with COPD-PH and a precapillary hemodynamic component. Among these, 71% (n = 10) had isolated precapillary PH and 29% (n = 4) had combined pre- and postcapillary PH. Based on prior definitions, 71% (n = 10) met criteria for severe PH (mPAP ≥35 mmHg or mPAP ≥25 mmHg and CI < 2 L/min/m2) [3], whereas 50% (n = 7) met severe PH criteria based on updated guidelines (PVR >5 WU) [9,10]. Their median age was 65.5 years (range 51–93), 57% (n = 8) were female, and 86% (n = 12) were African American. 57% (n = 8) were former smokers, and 43% (n = 6) were current smokers. All 14 patients had CT imaging available, of whom 71% (n = 10) had emphysema; 5/10 had centrilobular emphysema, 3/10 had pan lobular emphysema, and 2/10 had para-septal emphysema. Of 11 patients with spirometry available, 2/11 had GOLD grade 1 (mild airflow obstruction), 5/11 had GOLD grade 2 (moderate airflow obstruction), 4/11 had GOLD grade 3 (severe airflow obstruction), and none had GOLD grade 4 (very severe airflow obstruction). Up to 50% (n = 7) had obstructive sleep apnea (OSA) and 36% (n = 5) were on home supplemental oxygen. Furthermore, cardiometabolic comorbidities were prevalent, including hypertension in 83% (n = 12), hyperlipidemia in 93% (n = 13), chronic kidney disease stage ≥3 in 64% (n = 9), and diabetes mellitus in 29% (n = 4) (see Table 1).Table 1Baseline characteristics and clinical outcomes.Table 1VariablesTotal (n = 14)Demographics, n (%)Age, years — Median (range)65.5 (51–93)Female sex, n (%)8 (57%)Race African American12 (86%) White2 (14%)Body mass index (kg/m2) — Median (range)34.6 (17.9–53.6)Pulmonary comorbidities, n (%)Chronic obstructive pulmonary disease14 (100%)Emphysema10 (71%)Centrilobular5/10 (50%)Para-septal2/10 (20%)Pan-lobular3/10 (30%)Obstructive sleep apnea7 (50%)Asthma4 (29%)Smoking status Current smoker6 (43%) Former smoker8 (57%)Smoking pack-years — Median (range)30 (7.5–50)Supplemental oxygen use5 (36%)Cardiovascular comorbidities, n (%)Hypertension12 (83%)Diabetes mellitus4 (29%)Hyperlipidemia13 (93%)Heart failure13 (93%) HFrEF4/13 (31%) HFpEF9/13 (69%)Atrial fibrillation6 (43%)Chronic kidney disease stage ≥39 (64%)Prior venous thromboembolism1 (7%)Pulmonary hemodynamic data (RHC) — Median (range)Mean PA pressure (mmHg)42 (24–58)Pulmonary artery wedge pressure (mmHg)12 (5–29)Pulmonary vascular resistance (Wood units)5.6 (2.7–12.3)Cardiac index (L/min/m2)2.7 (1.6–3.8)Cardiac output (L/min)5.5 (3.4–8.5)Isolated precapillary PH10 (71%)Combined pre- and postcapillary PH4 (29%)Severe PH (PVR >5 WU)7 (50%)Severe PH (mPAP ≥35 mmHg or mPAP ≥25 mmHg and CI < 2 L/min/m2)10 (71%)Echocardiographic Findings — Median (range)Estimated left ventricular ejection fraction (%) (n = 14)55 (15–75)Left atrial dilation, n (%) (n = 14)5 (36%)Estimated PA systolic pressure (mmHg) (n = 12)68.5 (40–105)Tricuspid regurgitation velocity (m/sec) (n = 13)3.15 (2–4.8)Right ventricular dilation, n (%) (n = 14)12 (86%)Right atrial dilation (n = 14)9 (64%)Spirometry/Polysomnography — Median (range)FEV1/FVC ratio (n = 11)0.66 (0.36–0.72)FEV 1 sec, L (n = 11)1.58 (0.72–2.6)FEV 1 sec, % predicted (n = 11)0.53 (0.36–0.94)FVC, L (n = 11)1.48 (0.72–2.63)FVC, % predicted (n = 11)0.78 (0.47–1.03)DLCO, mL/min/mmHg (n = 9)11.3 (3.1–26.7)DLCO % predicted (n = 9)0.42 (0.26–0.80)Pulmonary vasodilator therapy, n (%)PDE-5 inhibitor14 (100%)Endothelin receptor antagonist1 (7%)Monotherapy13 (92%)Combination therapy1 (7%)Clinical Outcomes (1-year follow-up), n (%) (n=13)Major adverse cardiovascular events5 (38%)Cardiovascular death2 (15%)Heart failure exacerbation3 (23%)All-cause mortality2 (15%)Abbreviations: CI, cardiac index; CKD, chronic kidney disease; CO, cardiac output; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity of the lung for carbon monoxide; eLVEF, estimated left ventricular ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; ILD, interstitial lung disease; LA, left atrium; mPAP, mean pulmonary artery pressure; OSA, obstructive sleep apnea; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase type 5; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RA, right atrium; RHC, right heart catheterization; RV, right ventricle; TRV, tricuspid regurgitation velocity. Table 1Baseline characteristics and clinical outcomes.Table 1VariablesTotal (n = 14)Demographics, n (%)Age, years — Median (range)65.5 (51–93)Female sex, n (%)8 (57%)Race African American12 (86%) White2 (14%)Body mass index (kg/m2) — Median (range)34.6 (17.9–53.6)Pulmonary comorbidities, n (%)Chronic obstructive pulmonary disease14 (100%)Emphysema10 (71%)Centrilobular5/10 (50%)Para-septal2/10 (20%)Pan-lobular3/10 (30%)Obstructive sleep apnea7 (50%)Asthma4 (29%)Smoking status Current smoker6 (43%) Former smoker8 (57%)Smoking pack-years — Median (range)30 (7.5–50)Supplemental oxygen use5 (36%)Cardiovascular comorbidities, n (%)Hypertension12 (83%)Diabetes mellitus4 (29%)Hyperlipidemia13 (93%)Heart failure13 (93%) HFrEF4/13 (31%) HFpEF9/13 (69%)Atrial fibrillation6 (43%)Chronic kidney disease stage ≥39 (64%)Prior venous thromboembolism1 (7%)Pulmonary hemodynamic data (RHC) — Median (range)Mean PA pressure (mmHg)42 (24–58)Pulmonary artery wedge pressure (mmHg)12 (5–29)Pulmonary vascular resistance (Wood units)5.6 (2.7–12.3)Cardiac index (L/min/m2)2.7 (1.6–3.8)Cardiac output (L/min)5.5 (3.4–8.5)Isolated precapillary PH10 (71%)Combined pre- and postcapillary PH4 (29%)Severe PH (PVR >5 WU)7 (50%)Severe PH (mPAP ≥35 mmHg or mPAP ≥25 mmHg and CI < 2 L/min/m2)10 (71%)Echocardiographic Findings — Median (range)Estimated left ventricular ejection fraction (%) (n = 14)55 (15–75)Left atrial dilation, n (%) (n = 14)5 (36%)Estimated PA systolic pressure (mmHg) (n = 12)68.5 (40–105)Tricuspid regurgitation velocity (m/sec) (n = 13)3.15 (2–4.8)Right ventricular dilation, n (%) (n = 14)12 (86%)Right atrial dilation (n = 14)9 (64%)Spirometry/Polysomnography — Median (range)FEV1/FVC ratio (n = 11)0.66 (0.36–0.72)FEV 1 sec, L (n = 11)1.58 (0.72–2.6)FEV 1 sec, % predicted (n = 11)0.53 (0.36–0.94)FVC, L (n = 11)1.48 (0.72–2.63)FVC, % predicted (n = 11)0.78 (0.47–1.03)DLCO, mL/min/mmHg (n = 9)11.3 (3.1–26.7)DLCO % predicted (n = 9)0.42 (0.26–0.80)Pulmonary vasodilator therapy, n (%)PDE-5 inhibitor14 (100%)Endothelin receptor antagonist1 (7%)Monotherapy13 (92%)Combination therapy1 (7%)Clinical Outcomes (1-year follow-up), n (%) (n=13)Major adverse cardiovascular events5 (38%)Cardiovascular death2 (15%)Heart failure exacerbation3 (23%)All-cause mortality2 (15%)Abbreviations: CI, cardiac index; CKD, chronic kidney disease; CO, cardiac output; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity of the lung for carbon monoxide; eLVEF, estimated left ventricular ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; ILD, interstitial lung disease; LA, left atrium; mPAP, mean pulmonary artery pressure; OSA, obstructive sleep apnea; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase type 5; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RA, right atrium; RHC, right heart catheterization; RV, right ventricle; TRV, tricuspid regurgitation velocity. Baseline characteristics and clinical outcomes. Abbreviations: CI, cardiac index; CKD, chronic kidney disease; CO, cardiac output; COPD, chronic obstructive pulmonary disease; DLCO, diffusion capacity of the lung for carbon monoxide; eLVEF, estimated left ventricular ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; ILD, interstitial lung disease; LA, left atrium; mPAP, mean pulmonary artery pressure; OSA, obstructive sleep apnea; PA, pulmonary artery; PCWP, pulmonary capillary wedge pressure; PDE-5, phosphodiesterase type 5; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RA, right atrium; RHC, right heart catheterization; RV, right ventricle; TRV, tricuspid regurgitation velocity. Regarding pulmonary vasodilator therapy, all patients received PDE-5 inhibitor therapy with sildenafil. Most patients (13/14) received monotherapy, whereas only one patient (subject 4) with severe precapillary PH received it in combination therapy with an endothelin receptor antagonist (macitentan). Individualized prescription patterns, including dosages and frequency of administration, are shown in Table 2.Table 2Individualized clinical data of patients with precapillary or combined pulmonary hypertension treated with pulmonary vasodilator therapy.Table 2Demographic dataComorbiditiesLung physiology dataPH classification and severityBaseline RHC dataFollow-up RHC dataTime between RHCPulmonary vasodilator therapyEchocardiography dataClinical outcomes at 1-year follow-upSubject 193-year-old woman, African AmericanCOPD/emphysema, CKD3, HTN, HLD, current smoker (30py)PFT not availableNot on supplemental oxygenPrecapillary, non-severemPAP 31, PCWP 5, PVR 4.7, CO 5.5, CI 3None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal diastolic function, normal LA size. TRV 2.0 m/sec, RV and RA dilation.Died after palliative extubation due to out-of-hospital cardiac arrest 49 days after RHC.Subject 251-year-old man, African AmericanCOPD, OSA (AHI-NA), HTN, CKD3, HF, former smoker (7.5py)FEV1/FVC 0.63, FEV1 53% predicted, DLCO 80% predicted. GOLD 2Not on supplemental oxygenCombined, severe PHmPAP 55, PCWP 22, PVR 5.5, CO 6, CI 2.3mPAP 40, PCWP 30, PVR 1.7, CO 6.1, CI 2.310 monthsSildenafil 20 \mg TIDReduced eLVEF 15%, LA dilation. TRV not reported. RV dilation, normal RA size.Admitted due to HF exacerbation 249 days after RHC. Last known alive 450 days after RHC.Subject 376-year-old woman, African AmericanCOPD, HF, HTN, asthma, CKD3, HF, current smoker (20 py)FEV1/FVC 0.56, FEV1 47% predicted, DLCO 42% predicted. GOLD 3Not on supplemental oxygenPrecapillary, severe PHmPAP 58, PCWP 13, PVR 6.7, CO 6.6, CI 3.3None–Sildenafil 20 mg TIDNormal eLVEF 65%, diastolic dysfunction, LA dilation. TRV 3.7 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Died 518 days after RHC.Subject 453-year-old man, WhiteCOPD, HF, HTN, CKD1, cirrhosis, former smoker (25 py)FEV1/FVC 0.69, FEV1 73% predicted, DLCO 63% predicted. GOLD 2Not on supplemental oxygenPrecapillary, severe PHmPAP 50, PCWP 7, PVR 5.4, CO 7.9, CI 3.1mPAP 54, PCWP 6, PVR 8.3, CO 5.8, CI 2.23 yearsSildenafil 20 mg TID + macitentan 10 mg dailyNormal eLVEF 50%, normal LA size. TRV 3.8 m/sec, RV dilated, normal RA size.No adverse outcomes within 1 year of follow-up. Last known alive 2277 days after RHC.Subject 576-year-old man, African AmericanCOPD/emphysema, OSA (AHI 46), HF, DM, HTN, VTE, CKD4, former smoker (30 py)FEV1/FVC 0.69, FEV1 94% predicted, DLCO NA. GOLD 1On 4L supplemental oxygen.Combined, severe PHmPAP 35, PCWP 16, PVR 4.2, CO 4.5, CI 1.8mPAP 32, PCWP 11, PVR 5.3, CO 4, CI 1.79 monthsSildenafil 20 mg TIDReduced eLVEF 15%, diastolic dysfunction, LA dilation. TRV 2.07 m/sec, RV and RA dilation.HF exacerbation 92 days after RHC. Last known alive 1098 days after RHC.Subject 659-year-old woman, African AmericanAsthma, COPD/emphysema, OSA (AHI-NA), CKD1, former smoker (40 py).FEV1/FVC 0.71, FEV1 85% predicted, DLCO 54% GOLD 1 Not on supplemental oxygenPrecapillary, severe PHmPAP 50, PCWP 8, PVR 12.3, CO 3.4, CI 2.0None–Sildenafil 20 mg TIDNormal eLVEF 50%, normal LA size. TRV 4.09 m/sec, RV and RA dilation.No adverse pulmonary or cardiovascular outcomes; Last known alive 1492 days after RHCSubject 774-year-old man, WhiteCOPD/emphysema, OSA, HF, DM, HTN, CKD1, current smoker (30 py).FEV1/FVC 0.72, FEV1 47% predicted, DLCO 40% predicted. GOLD 3On 3L supplemental oxygen.Precapillary, non-severe PHmPAP 30, PCWP 10, PVR 4.1, CO 4.8, CI 2.2None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal LA size. TRV 3.24 m/sec, RV dilated, normal RA size.No adverse outcomes within 1 year of follow-up. Last known alive 355 days after RHC.Subject 871-year-old woman, African AmericanCOPD/emphysema, ILD, HF, HTN, CKD3, SLE, current smoker (30 py).FEV1/FVC 0.42, FEV1 50% predicted. GOLD 2On 2L supplemental oxygen.Precapillary, non-severe PHmPAP 24, PCWP 5, PVR 4.8, CO 3.9, CI 2.8None–Sildenafil 20 mg TIDReduced eLVEF 45%, normal LA size. TRV 2.05 m/sec, RV and RA dilation.Died 31 days after RHC due to cardiogenic shock. He died after palliative extubation.Subject 966-year-old woman, African AmericanCOPD/Emphysema, OSA (AHI NA), HF, HTN, CKD2, current smoker (50 py).FEV1/FVC 0.72, FEV1 66% predicted. DLCO NA. GOLD 2Not on supplemental oxygenPrecapillary, severe PHmPAP 41, PCWP 9, PVR 5.6, CO 5.73, CI 2.8None–Sildenafil 20 mg TIDNormal eLVEF 55%, DD NA, ePASP 80 mmHg, TRV 2.044, RA dilation absent, moderate, RV dilation, LA dilation absent, TAPSE NAAdmitted due to HF exacerbation 200 days after RHC. Last known alive 556 days after RHC.Subject 1065-year-old man, African AmericanCOPD, HF, HTN, CKD5, current smoker (25 py).FEV1/FVC 0.36, FEV1 36% predicted, DLCO 70% predicted. GOLD 3Not on supplemental oxygenPrecapillary, non-severe PHmPAP 33, PCWP 5, PVR 4.7, CO 5.9, CI 3.4mPAP 43, PCWP 3, PVR 6.6, CO 6, CI 3.64 yearsSildenafil 20 mg TIDNormal eLVEF 55%, Diastolic dysfunction, LA dilation. TRV 3.35 m/sec, Normal RV and RA size.No adverse outcomes within 1 year of follow-up. Died 1618 days after RHC.Subject 1173-year-old woman, African AmericanCOPD/emphysema, HF, CKD3, SLE, former smoker (30 py).FEV1/FVC 0.66, FEV1 71% predicted, DLCO 30%. GOLD 2On 3L supplemental oxygen.Precapillary, severe PHmPAP 41, PCWP 14, PVR 4.7, CO 6.0, CI 3.5None–Sildenafil 20 mg TIDReduced eLVEF 45%, diastolic dysfunction, LA dilation. TRV 2.03 m/sec, normal RV and RA size.No adverse outcomes within 1 year of follow-up. Last known alive 1982 days after RHC.Subject 1262-year-old woman, African AmericanCOPD/emphysema, asthma, OSA, HF, HTN, former smoker (40 py).FEV1/FVC 0.52, FEV1 48% predicted, DLCO 40%. GOLD 3Not on supplemental oxygen, CPAP useCombined, severe PHmPAP 52, PCWP 29, PVR 2.7, CO 8.5, CI 3.8None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal diastolic function, normal LA size. TRV 3.9 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 1377 days after RHC.Subject 1360-year-old man, African AmericanCOPD/emphysema, asthma, HTN, CKD2, former smoker (50 py).PFT not available. On 2L supplemental oxygen.Precapillary, severe PHmPAP 39, PCWP 11, PVR 7.5, CO 3.7, CI 1.6None–Sildenafil 20 mg TIDNormal eLVEF 60%, normal diastolic function, normal LA size. TRV 3.3 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 5 days after RHC.Subject 1457-year-old womanAfrican AmericanCOPD/Emphysema, OSA, HF, former smoker (40 py).PFT not available.Not on supplemental oxygenCombined, severe PHmPAP 44, PCWP 20, PVR 5.3, CO 4.57\, CI 2.2None–Sildenafil 20 mg TIDHyperdynamic eLVEF 70%, normal LA size. TRV 3.88 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 1283 days after RHC.Abbreviations: CI: cardiac index. CKD: chronic kidney disease. CO: cardiac output. COPD: chronic obstructive pulmonary disease. DLCO: diffusion lung capacity of carbon monoxide. eLVEF: estimated left ventricular ejection fraction. HTN: hypertension. LA: left atrium. mPAP: mean pulmonary artery pressure. OSA: obstructive sleep apnea. PCWP: pulmonary capillary wedge pressure. PFT: pulmonary function testing. PH: pulmonary hypertension. PVR: pulmonary vascular resistance. RA: right atrium. RHC: right heart catheterization. RV: right ventricle. TRV: tricuspid regurgitation velocity. HF: heart failure. HLD: hyperlipidemia. DM: diabetes mellitus. VTE: venous thromboembolism. ILD: interstitial lung disease. SLE: systemic lupus erythematosus. GOLD: Global Initiative for Chronic Obstructive Lung Disease. TAPSE: tricuspid annular plane systolic excursion. ePASP: estimated pulmonary artery systolic pressure. AHI: apnea–hypopnea index. CPAP: continuous positive airway pressure. Table 2Individualized clinical data of patients with precapillary or combined pulmonary hypertension treated with pulmonary vasodilator therapy.Table 2Demographic dataComorbiditiesLung physiology dataPH classification and severityBaseline RHC dataFollow-up RHC dataTime between RHCPulmonary vasodilator therapyEchocardiography dataClinical outcomes at 1-year follow-upSubject 193-year-old woman, African AmericanCOPD/emphysema, CKD3, HTN, HLD, current smoker (30py)PFT not availableNot on supplemental oxygenPrecapillary, non-severemPAP 31, PCWP 5, PVR 4.7, CO 5.5, CI 3None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal diastolic function, normal LA size. TRV 2.0 m/sec, RV and RA dilation.Died after palliative extubation due to out-of-hospital cardiac arrest 49 days after RHC.Subject 251-year-old man, African AmericanCOPD, OSA (AHI-NA), HTN, CKD3, HF, former smoker (7.5py)FEV1/FVC 0.63, FEV1 53% predicted, DLCO 80% predicted. GOLD 2Not on supplemental oxygenCombined, severe PHmPAP 55, PCWP 22, PVR 5.5, CO 6, CI 2.3mPAP 40, PCWP 30, PVR 1.7, CO 6.1, CI 2.310 monthsSildenafil 20 \mg TIDReduced eLVEF 15%, LA dilation. TRV not reported. RV dilation, normal RA size.Admitted due to HF exacerbation 249 days after RHC. Last known alive 450 days after RHC.Subject 376-year-old woman, African AmericanCOPD, HF, HTN, asthma, CKD3, HF, current smoker (20 py)FEV1/FVC 0.56, FEV1 47% predicted, DLCO 42% predicted. GOLD 3Not on supplemental oxygenPrecapillary, severe PHmPAP 58, PCWP 13, PVR 6.7, CO 6.6, CI 3.3None–Sildenafil 20 mg TIDNormal eLVEF 65%, diastolic dysfunction, LA dilation. TRV 3.7 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Died 518 days after RHC.Subject 453-year-old man, WhiteCOPD, HF, HTN, CKD1, cirrhosis, former smoker (25 py)FEV1/FVC 0.69, FEV1 73% predicted, DLCO 63% predicted. GOLD 2Not on supplemental oxygenPrecapillary, severe PHmPAP 50, PCWP 7, PVR 5.4, CO 7.9, CI 3.1mPAP 54, PCWP 6, PVR 8.3, CO 5.8, CI 2.23 yearsSildenafil 20 mg TID + macitentan 10 mg dailyNormal eLVEF 50%, normal LA size. TRV 3.8 m/sec, RV dilated, normal RA size.No adverse outcomes within 1 year of follow-up. Last known alive 2277 days after RHC.Subject 576-year-old man, African AmericanCOPD/emphysema, OSA (AHI 46), HF, DM, HTN, VTE, CKD4, former smoker (30 py)FEV1/FVC 0.69, FEV1 94% predicted, DLCO NA. GOLD 1On 4L supplemental oxygen.Combined, severe PHmPAP 35, PCWP 16, PVR 4.2, CO 4.5, CI 1.8mPAP 32, PCWP 11, PVR 5.3, CO 4, CI 1.79 monthsSildenafil 20 mg TIDReduced eLVEF 15%, diastolic dysfunction, LA dilation. TRV 2.07 m/sec, RV and RA dilation.HF exacerbation 92 days after RHC. Last known alive 1098 days after RHC.Subject 659-year-old woman, African AmericanAsthma, COPD/emphysema, OSA (AHI-NA), CKD1, former smoker (40 py).FEV1/FVC 0.71, FEV1 85% predicted, DLCO 54% GOLD 1 Not on supplemental oxygenPrecapillary, severe PHmPAP 50, PCWP 8, PVR 12.3, CO 3.4, CI 2.0None–Sildenafil 20 mg TIDNormal eLVEF 50%, normal LA size. TRV 4.09 m/sec, RV and RA dilation.No adverse pulmonary or cardiovascular outcomes; Last known alive 1492 days after RHCSubject 774-year-old man, WhiteCOPD/emphysema, OSA, HF, DM, HTN, CKD1, current smoker (30 py).FEV1/FVC 0.72, FEV1 47% predicted, DLCO 40% predicted. GOLD 3On 3L supplemental oxygen.Precapillary, non-severe PHmPAP 30, PCWP 10, PVR 4.1, CO 4.8, CI 2.2None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal LA size. TRV 3.24 m/sec, RV dilated, normal RA size.No adverse outcomes within 1 year of follow-up. Last known alive 355 days after RHC.Subject 871-year-old woman, African AmericanCOPD/emphysema, ILD, HF, HTN, CKD3, SLE, current smoker (30 py).FEV1/FVC 0.42, FEV1 50% predicted. GOLD 2On 2L supplemental oxygen.Precapillary, non-severe PHmPAP 24, PCWP 5, PVR 4.8, CO 3.9, CI 2.8None–Sildenafil 20 mg TIDReduced eLVEF 45%, normal LA size. TRV 2.05 m/sec, RV and RA dilation.Died 31 days after RHC due to cardiogenic shock. He died after palliative extubation.Subject 966-year-old woman, African AmericanCOPD/Emphysema, OSA (AHI NA), HF, HTN, CKD2, current smoker (50 py).FEV1/FVC 0.72, FEV1 66% predicted. DLCO NA. GOLD 2Not on supplemental oxygenPrecapillary, severe PHmPAP 41, PCWP 9, PVR 5.6, CO 5.73, CI 2.8None–Sildenafil 20 mg TIDNormal eLVEF 55%, DD NA, ePASP 80 mmHg, TRV 2.044, RA dilation absent, moderate, RV dilation, LA dilation absent, TAPSE NAAdmitted due to HF exacerbation 200 days after RHC. Last known alive 556 days after RHC.Subject 1065-year-old man, African AmericanCOPD, HF, HTN, CKD5, current smoker (25 py).FEV1/FVC 0.36, FEV1 36% predicted, DLCO 70% predicted. GOLD 3Not on supplemental oxygenPrecapillary, non-severe PHmPAP 33, PCWP 5, PVR 4.7, CO 5.9, CI 3.4mPAP 43, PCWP 3, PVR 6.6, CO 6, CI 3.64 yearsSildenafil 20 mg TIDNormal eLVEF 55%, Diastolic dysfunction, LA dilation. TRV 3.35 m/sec, Normal RV and RA size.No adverse outcomes within 1 year of follow-up. Died 1618 days after RHC.Subject 1173-year-old woman, African AmericanCOPD/emphysema, HF, CKD3, SLE, former smoker (30 py).FEV1/FVC 0.66, FEV1 71% predicted, DLCO 30%. GOLD 2On 3L supplemental oxygen.Precapillary, severe PHmPAP 41, PCWP 14, PVR 4.7, CO 6.0, CI 3.5None–Sildenafil 20 mg TIDReduced eLVEF 45%, diastolic dysfunction, LA dilation. TRV 2.03 m/sec, normal RV and RA size.No adverse outcomes within 1 year of follow-up. Last known alive 1982 days after RHC.Subject 1262-year-old woman, African AmericanCOPD/emphysema, asthma, OSA, HF, HTN, former smoker (40 py).FEV1/FVC 0.52, FEV1 48% predicted, DLCO 40%. GOLD 3Not on supplemental oxygen, CPAP useCombined, severe PHmPAP 52, PCWP 29, PVR 2.7, CO 8.5, CI 3.8None–Sildenafil 20 mg TIDNormal eLVEF 55%, normal diastolic function, normal LA size. TRV 3.9 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 1377 days after RHC.Subject 1360-year-old man, African AmericanCOPD/emphysema, asthma, HTN, CKD2, former smoker (50 py).PFT not available. On 2L supplemental oxygen.Precapillary, severe PHmPAP 39, PCWP 11, PVR 7.5, CO 3.7, CI 1.6None–Sildenafil 20 mg TIDNormal eLVEF 60%, normal diastolic function, normal LA size. TRV 3.3 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 5 days after RHC.Subject 1457-year-old womanAfrican AmericanCOPD/Emphysema, OSA, HF, former smoker (40 py).PFT not available.Not on supplemental oxygenCombined, severe PHmPAP 44, PCWP 20, PVR 5.3, CO 4.57\, CI 2.2None–Sildenafil 20 mg TIDHyperdynamic eLVEF 70%, normal LA size. TRV 3.88 m/sec, RV and RA dilation.No adverse outcomes within 1 year of follow-up. Last known alive 1283 days after RHC.Abbreviations: CI: cardiac index. CKD: chronic kidney disease. CO: cardiac output. COPD: chronic obstructive pulmonary disease. DLCO: diffusion lung capacity of carbon monoxide. eLVEF: estimated left ventricular ejection fraction. HTN: hypertension. LA: left atrium. mPAP: mean pulmonary artery pressure. OSA: obstructive sleep apnea. PCWP: pulmonary capillary wedge pressure. PFT: pulmonary function testing. PH: pulmonary hypertension. PVR: pulmonary vascular resistance. RA: right atrium. RHC: right heart catheterization. RV: right ventricle. TRV: tricuspid regurgitation velocity. HF: heart failure. HLD: hyperlipidemia. DM: diabetes mellitus. VTE: venous thromboembolism. ILD: interstitial lung disease. SLE: systemic lupus erythematosus. GOLD: Global Initiative for Chronic Obstructive Lung Disease. TAPSE: tricuspid annular plane systolic excursion. ePASP: estimated pulmonary artery systolic pressure. AHI: apnea–hypopnea index. CPAP: continuous positive airway pressure. Individualized clinical data of patients with precapillary or combined pulmonary hypertension treated with pulmonary vasodilator therapy. Abbreviations: CI: cardiac index. CKD: chronic kidney disease. CO: cardiac output. COPD: chronic obstructive pulmonary disease. DLCO: diffusion lung capacity of carbon monoxide. eLVEF: estimated left ventricular ejection fraction. HTN: hypertension. LA: left atrium. mPAP: mean pulmonary artery pressure. OSA: obstructive sleep apnea. PCWP: pulmonary capillary wedge pressure. PFT: pulmonary function testing. PH: pulmonary hypertension. PVR: pulmonary vascular resistance. RA: right atrium. RHC: right heart catheterization. RV: right ventricle. TRV: tricuspid regurgitation velocity. HF: heart failure. HLD: hyperlipidemia. DM: diabetes mellitus. VTE: venous thromboembolism. ILD: interstitial lung disease. SLE: systemic lupus erythematosus. GOLD: Global Initiative for Chronic Obstructive Lung Disease. TAPSE: tricuspid annular plane systolic excursion. ePASP: estimated pulmonary artery systolic pressure. AHI: apnea–hypopnea index. CPAP: continuous positive airway pressure. Four patients (subjects 2, 4, 5, and 10) underwent repeated hemodynamic evaluation, with a median time between index and follow-up RHC of 23 months (range 9 months to 4 years). Two patients (subjects 4 and 10) had isolated precapillary PH, and two patients (subjects 2 and 5) had combined pre- and postcapillary PH. In ¾ of patients, their PVR increased at subsequent RHCs, whereas their PAWP remained stable, including the single subject who was treated with combination therapy (Fig. 1). Only 1 patient (subject 2) had lower PVR on follow-up RHC; this patient had severe combined pre- and postcapillary PH, an increase in PAWP from 22 to 30 mmHg, and developed an episode of heart failure exacerbation 249 days after RHC.Fig. 1Individual hemodynamic trajectories following pulmonary vasodilator therapy in COPD-Associated pulmonary hypertension. Individual hemodynamic trajectories following pulmonary vasodilator therapy in COPD-Associated pulmonary hypertension. At 1-year follow-up, one patient (subject 13) was lost to follow-up. Of 13 patients with 1-year follow-up data available, 38% (n = 5) of patients developed a major adverse cardiovascular event (MACE), including 3/5 episodes of heart failure exacerbations requiring hospitalization, and 2/5 who experienced cardiovascular death. The median time from index RHC to first cardiovascular event within 1 year was 4 months (range 1–8 months). Of these patients, all had evidence of RV dysfunction on TTE; 3/5 had reduced LV ejection fraction on TTE, and 2/5 had normal systolic and diastolic left ventricular function on TTE. Notably, we did not observe any pulmonary outcomes in patients with COPD-PH during the 1-year follow-up period. Discussion In this single-center case series, we describe 14 patients with RHC-confirmed COPD-PH and a precapillary hemodynamic component who were treated with pulmonary vasodilator therapy in routine clinical practice. The main finding is that vasodilator therapy was used infrequently, in only 7% of patients with COPD-PH and a precapillary component, and primarily as sildenafil monotherapy. Treated patients represented a clinically complex and highly selected group, with frequent cardiovascular comorbidities, RV abnormalities, severe PH features, and heterogeneous hemodynamic profiles. During follow-up, cardiovascular events were common, and repeat RHC, when available, showed variable but often unfavorable pulmonary vascular trajectories. The clinical value of this case series lies in its patient-level description of real-world treatment selection in COPD-PH. While prior trials and registry studies have evaluated treatment efficacy, they do not fully capture how clinicians select patients for off-label pulmonary vasodilator therapy in daily practice, particularly in centers caring for patients with multiple cardiopulmonary comorbidities. Our cohort illustrates that treated patients often have overlapping features of pulmonary vascular disease, COPD, sleep-disordered breathing, left heart disease, and chronic kidney disease, making treatment decisions difficult and emphasizing the need for careful hemodynamic phenotyping before therapy. In our cohort, more than 70% of patients treated with pulmonary vasodilators had isolated precapillary PH, while the remaining had combined pre- and postcapillary PH, underscoring the heterogeneous hemodynamic profiles observed in COPD-PH. Furthermore, patients in this study exhibited a high burden of cardiopulmonary comorbidities, including hypertension, hyperlipidemia, and obstructive sleep apnea in more than 50% of patients, reflecting the complex interplay between pulmonary comorbidities and cardiovascular risk factors. Notably, most patients were African American, reflecting the population served by our institution. This is relevant because racial and ethnic minority populations remain underrepresented in pulmonary vascular clinical studies [11]. Although our sample size is small and not designed to compare outcomes by race, this case series contributes patient-level data from a population that is often less visible in clinical trial literature. The most frequently used pulmonary vasodilator was sildenafil as a single agent, except for one patient who received combination therapy with sildenafil and macitentan. PDE5i mediates pulmonary vasodilation by potentiating nitric oxide signaling. Furthermore, PDE5i have been described to improve diastolic function by preventing and reversing myocardial hypertrophy, a common finding in patients with COPD [12]. Meanwhile, endothelin receptor antagonists (ERA), such as macitentan, are potent pulmonary vasodilators that target the endothelin receptor-A, promoting vasodilation and preventing cell proliferation [13]. These are increasingly used in combination therapy with PDE5i in patients with pulmonary arterial hypertension [14]. Among patients with COPD-PH, the use of pulmonary vasodilators has not been approved. A prior randomized controlled trial (RCT) testing ERA (bosentan) showed no clinical benefits in terms of lung function, pulmonary hemodynamics, or exercise capacity, but instead caused worsening hypoxemia, deemed secondary to worsening ventilation-perfusion (V/Q) mismatch [15]. Another RCT testing PDE5i (tadalafil) in COPD-PH demonstrated no improvement in exercise capacity or quality of life despite exerting pulmonary vasodilation [16]. To overcome potential issues associated with V/Q mismatch, a recent RCT tested inhaled treprostinil among patients with COPD-associated PH. The novel administration of pulmonary vasodilators via inhalation enhances pulmonary vasodilation in well-ventilated lung regions, thereby promoting V/Q matching, as seen in patients with idiopathic pulmonary fibrosis [17]. Unfortunately, this study was terminated early by the data safety monitoring board due to futility and the increased risk of serious adverse events among those treated with inhaled treprostinil [4]. In our study, more than one-third of patients with COPD-PH treated with pulmonary vasodilators developed cardiovascular outcomes at 1-year follow-up. Furthermore, among patients with available follow-up hemodynamic data, 3 of 4 had higher PVR on repeat RHC, while PAWP remained stable or decreased. In contrast, one patient had lower PVR on follow-up RHC, accompanied by higher PAWP. These findings should be interpreted in the context of a highly selected population with advanced pulmonary vascular disease, where 50% of patients met the current criteria of severe COPD-PH, and of a high burden of cardiovascular comorbidities. These findings reflect the complex and heterogeneous pathophysiology of COPD-PH, where increased PA pressures may be mediated by several mechanisms beyond hypoxic vasoconstriction, including pulmonary vascular stiffening and remodeling, parenchymal destruction (and vascular pruning), hyperinflation (and extrinsic compression of pulmonary vessels), and left heart disease (sometimes preclinical), potentially limiting the effectiveness of PDE5i therapy in targeting the dominant disease mechanisms as a single or combination therapy. Interestingly, unlike prior studies showing worsening V/Q mismatch in COPD-PH patients, we did not observe adverse pulmonary outcomes during follow-up. Overall, our findings complement prior randomized trials and registry studies by providing patient-level real-world data on the clinical complexity, treatment patterns, and follow-up trajectories of patients with COPD-PH selected for pulmonary vasodilator therapy [4,12,15,16]. Our study has several limitations. This case series is descriptive and should not be interpreted as evidence of treatment efficacy or harm. Furthermore, most patients were on single-agent therapy, and these findings should not be extrapolated to combination therapy strategies used in pulmonary arterial hypertension. Treatment decisions were based on clinical judgment rather than standardized protocols, which may introduce selection bias; for example, the only patient (subject 4) treated with combination therapy was the patient with the worst hemodynamic profile at the subsequent RHC, reflecting his underlying disease severity rather than treatment ineffectiveness. Additionally, follow-up hemodynamic data were available for only 29% of patients, limiting our ability to assess the hemodynamic trajectory in the remaining 71%; however, the hemodynamic patterns observed correlate with previously published data. Lastly, most patients in our population were African American and had many cardiopulmonary comorbidities, which makes it challenging to generalize our data to other COPD groups. Nevertheless, our study provides relevant data regarding this subgroup of patients who are frequently excluded from clinical trials. In this real-world case series, pulmonary vasodilator therapy was used in a small, highly selected subset of patients with RHC-confirmed COPD-PH and a precapillary component. Treated patients had heterogeneous hemodynamic profiles, frequent cardiopulmonary comorbidities, and a high burden of cardiovascular events during follow-up. These findings highlight the need for careful phenotyping and prospective studies to define which COPD-PH patients, if any, may benefit from pulmonary vasodilator therapy. CRediT authorship contribution statement Michael Vera Ricaurte: Conceptualization, Methodology, Writing – original draft. Esteban Kosak Lopez: Data curation, Formal analysis, Investigation, Methodology, Supervision, Writing – review & editing. Andrew Geller: Data curation. Raul Leguizamon: Data curation, Supervision. Justin Lam: Data curation, Supervision. Thitiphan Srikulmontri: Data curation, Supervision. Maria Helena Siqueira Tavares de Melo: Data curation, Supervision. Thomas Stavola: Data curation, Supervision. John Malin: Data curation, Supervision. Jose M. Martinez-Manzano: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. Enrique Pacheco: Conceptualization, Investigation, Supervision, Visualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.